A Randomized Double-blinded Trial Comparing DEsmopressin to FEsoterodine in the Treatment of Severe Nocturia in Women Aged 65 and olDer: The DEFEND Trial

Trial Profile

A Randomized Double-blinded Trial Comparing DEsmopressin to FEsoterodine in the Treatment of Severe Nocturia in Women Aged 65 and olDer: The DEFEND Trial

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs Fesoterodine (Primary) ; Desmopressin
  • Indications Nocturia
  • Focus Therapeutic Use
  • Acronyms DEFEND trial
  • Most Recent Events

    • 11 Nov 2016 Status changed from not yet recruiting to discontinued.
    • 20 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top